地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18771997407
邮箱:sales@amyjet.com

PANAGENE公司成立于2006年,以独有的肽核酸技术,为全世界范围内的客户提供高纯度的肽核酸产品。PNA(peptide nucleic acids,PNA)肽核酸技术,是90年代丹麦科学家发明的一类以多肽骨架取代糖磷酸主链的DNA类似物,即以中性的肽链酰胺2-氨基乙基甘氨酸键取代了DNA中的戊糖磷酸二酯键骨架,其余的与DNA相同,PNA可以通过Watson-Crick碱基配对的形式识别并结合DNA或RNA序列,形成稳定的双螺旋结构。
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest number of patents on the PNA and its applications in the world.
PANAGENE的主要产品包括:
Custom PNA synthesis
Gamma PNA
PNA FISH probe
PNAs™ miRNA inhibitor
Globin Reduction PNA
Fmoc PNA monomer
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Repligen是一家致力于开发和生产用于生物制药的材料的美国公司。
Repligen is a bioprocessing-focused life sciences company bringing over 35 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies.
Repligen公司的主要产品:
(1)UPSTREAM SOLUTIONS
XCell™ ATF System
Spectrum Filtration
Cell Culture Supplements
(2)DOWNSTREAM SOLUTIONS
OPUS® Pre-packed Chromatography Columns
Spectrum Filtration
TangenX™ TFF Cassettes
Protein A Affinity Resins
Protein A Ligands
(3)ANALYTICS
ELISA Kits
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Repligen"> Repligenhttp://www.amyjet.com/Index/lists/catid/99/kid/56.html
| 产品名称 | 规格 |
| Ammonia/Iron Standard Kit (Verichem Laboratories; CAT#9040) | 5x15mL |
| Ammonia/Iron Standard Level F (Verichem Laboratories; CAT#9046) | 1x15mL |
| Bilirubin Standard Kit (Verichem Laboratories; CAT#9450) | 10x5mL |
| Bilirubin Standard, Level F (Verichem Laboratories; CAT#9436) | 2x5mL |
| Tru-Zero™ Bilirubin Standard (Verichem Laboratories; CAT#9456) | 2x5mL |
| Br2 Bilirubin Calibrator (Verichem Laboratories; CAT#9459) | 2x5mL |
| Carbon Dioxide Standard Kit (Verichem Laboratories; CAT#9210) | 5x15mL |
| Carbon Dioxide Standard, Level F (Verichem Laboratories; CAT#9216) | 1x15mL |
| Electrolyte Standard Kit (Verichem Laboratories; CAT#9200) | 5x15mL |
| Enzyme Er™ Verifier Kit (Verichem Laboratories; CAT#9410) | 6x5mL |
| Enzyme Er™ Verifier, Level G (Verichem Laboratories; CAT#9417) | 1x5mL |
| Ethanol Standard Kit (Verichem Laboratories; CAT#9670) | 6x5mL |
| Hdl Cholesterol Verifier Kit (Verichem Laboratories; CAT#9560) | 6x5mL |
| Matrix Plus™ Chemistry Reference Kit (Verichem Laboratories; CAT#9500) | 5x15mL |
| Matrix Plus™ Chemistry Reference, Level F (Verichem Laboratories; CAT#9506) | 1x15mL |
| Matrix Plus™ Cholesterol Reference Kit (Verichem Laboratories; CAT#9550) | 5x15mL |
| Matrix Plus™ Cholesterol Reference, Level F (Verichem Laboratories; CAT#9556) | 1x15mL |
| Microprotein Standard Kit (Verichem Laboratories; CAT#9480) | 5x15mL |
| Serum Ise Standard Kit (Verichem Laboratories; CAT#9240) | 5x15mL |
| Total Protein / Albumin Standard Kit (Verichem Laboratories; CAT#9460) | 5x15mL |
| Total Protein / Albumin Standard, Level F (Verichem Laboratories; CAT#9466) | 1x15mL |
| Urine Chemistry Standard Kit (Verichem Laboratories; CAT#9000) | 5x15mL |
| Urine Uric Acid Standard Kit (Verichem Laboratories; CAT#9020) | 5x5mL |

更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Verichem Laboratories"> Verichem Laboratories
艾美捷科技代理ADS Biotec核酸色谱柱系列产品,用于RNA、DNA的分离和纯化。
RNASep™ 和DNASep™ 柱由均匀的烷基化无孔或大孔聚苯乙烯-二乙烯基苯(PS-DVB)共聚物微球组成,提供优异的分辨率和优异的灵敏度。
柱可以与大多数HPLC系统一起使用,以实现一致的性能和更快的纯度评估。

OligoSep™ HC Cartridge – High Capacity Oligonucleotide Separation Column
货号:NUC-99-3560
![]()

RNASep™ Semi-Prep – Ultra High Capacity RNA Purification Column
货号:RPC-99-3015
![]()

RNASep™ Semi-Prep – High Capacity RNA Purification Column
货号:RPC-99-2110
![]()

RNASep™ Prep – RNA Purification Column
货号:RNA-99-3810
![]()

OligoSep™ Prep HC Cartridge – High Capacity Oligonucleotide Purification Column
货号:NUC-99-3860
![]()

OligoSep™ Cartridge – Oligonucleotide Analysis Column
货号:NUC-99-3550
![]()

DNASep™ HT Cartridge – High Throughput DNA Separation Column
货号:DNA-99-3710
![]()

DNASep™ Cartridge – DNA Separation Column
货号:DNA-99-3510
![]()

艾美捷科技代理Antigenix免疫学研究工具
ANTIGENIX AMERICA是一家致力于生物医学研究的免疫学研究产品供应商。ANTIGENIX AMERICA团队在免疫学研究试剂的生产、销售和服务方面拥有20多年的经验;产品应用范围包括:
细胞因子研究、流式细胞术、免疫组织学、蛋白质印迹、功能研究和ELISA。物种涵盖人、小鼠、大鼠、兔、猪和犬等。
产品包括:
Super-X Plex®流式专用细胞因子试剂盒
细胞因子ELISA试剂盒和ELISA构建试剂盒
重组细胞因子和生长因子
细胞因子和生长因子抗体
CD标记物抗体,病毒蛋白,粘附标记物
ELISA辅助试剂,二抗
< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Antigenix免疫学研究工具"> 艾美捷科技代理Antigenix免疫学研究工具
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

SurModics公司成立于1979年,拥有30多年的临床诊断、生物医药、科研产品研发和开发经验,是体外诊断技术的领先品牌。可提供多种产品,主要包括蛋白稳定剂、封闭剂、缓冲剂、比色底物及化学发光底物、和抗原、抗体等。
Surmodics is the global leader in surface modification technologies for vascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two acquisitions of Creagh Medical and NorMedix – recognized innovators in balloon catheters and delivery systems – we have combined capabilities in proprietary surface technologies, as well as device design, development and manufacturing that enable us to significantly increase the value we offer our medical device customers. We are focused on developing highly differentiated, total vascular device solutions to the most demanding clinical challenges. The company’s R&D pipeline is rich with novel innovations within the field of vascular medicine. Even as we expand our capabilities, our mission remains to improve the detection and treatment of disease.
Surmodics公司主要产品:
(1)蛋白稳定剂/封闭剂
免疫检测稳定剂(微量滴定板、乳胶小珠、磁珠);微阵列芯片稳定剂; 封闭剂;结合物稳定剂(AP,HRP);无BSA稳定剂;稳定剂包:包含免疫检测稳定剂、结合物稳定剂、无BSA稳定剂、可选择稳定剂各25ml。
(2)BioFX底物/终止剂
比色HRP底物、比色AP底物、化学发光HRP底物、化学发光AP底物、TMB底物、ABTS和pNPP底物。
(3)稀释液/缓冲液/IHC试剂/附属试剂
SurModics提供ELISA稀释液、清洗液、免疫组化试剂。
(4)DIARECT自身免疫和免疫疾病抗原
DIARECT自勉和免疫疾病抗原的质量和敏感性都经过校验。主要包括:ANCN相关疾病、自勉型肝炎和肝脏疾病、肾炎综合症、甲状腺自勉疾病、血栓栓塞综合症、莱姆病、肠炎、胃肠腹腔疾病、细小病毒等。
(5)BioFX抗体和链酶亲和素
SurModics IVD为免疫印迹、免疫组化、ELISpot、RIA、微阵列应用提供十种不同物种和六种宿主二抗。
(6)微阵列芯片
微阵列芯片通过共价键链接RNA、DNA和蛋白,使用方便,兼容性好,适用于大部分阵列和扫描设备。
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Surmodics"> Surmodics
Zedira是一家临床阶段的生物技术公司,专门从事转谷氨酰胺酶的研究,开发一系列小分子药物候选物。Zedira公司正致力于药物发现的前沿领域,该领域涉及阻止调节失调的转谷氨酰胺酶的小分子。此外,Zedira是一个全球品牌,专门用于转谷氨酰胺酶领域的研发和诊断试剂,其独特和高质量的产品有助于推动转谷氨酰胺酶的研究和应用。
Zedira is a clinical stage biotech company specialised in transglutaminase. Zedira conducts its own development of small molecular drug candidates. In doing so, the company is working at the cutting edge of drug discovery involving small molecules that block dysregulated transglutaminases. In addition, Zedira is a global brand for specialty reagents for research & development as well as diagnostics in the transglutaminase field. Numerous unique and high quality products help pushing forward transglutaminase-related science – both in academia and industry.
Zedira公司主要产品:
Transglutaminases
Microbial Transglutaminase
Assays and Substrates
Inhibitors
Antibodies and Microarrays
Proteases
Protein Labeling
Blood Coagulation
Cereal Proteins
Celiac Disease Products
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
Zedira产品详情请咨询我司客服人员:
| 产品编号 | 产品名称 | 产品规格 |
| A003 | Polyclonal antibody to human tissue transglutaminase (TG2) | 100 ug |
| A004 | Monoclonal antibody to tissue transglutaminase (TG2) | 100 ug |
| A008 | Polyclonal antibody to human transglutaminase 5 (TG5) | 500 ug |
| A011 | Monoclonal antibody to gliadin (clone XGY1) | 1 mg |
| A013 | Monoclonal antibody to gliadin (clone XGY7) | 1 mg |
| A014 | Polyclonal antibody to human tissue transglutaminase (TG2) | 500 ug |
| A015 | Polyclonal antibody to human epidermal transglutaminase (TG3) | 500 ug |
| A016 | Polyclonal antibody to human blood coagulation factor XIII (A-subunit) | 500 ug |
| A017 | Polyclonal antibody to human neuronal transglutaminase (TG6) | 500 ug |
| A018 | Polyclonal antibody to human keratinocyte transglutaminase (TGI) | 500 ug |
| A020 | Polyclonal antibody to microbial protransglutaminase (pro-MTG, pro-BTG) | 500 ug |
| A021 | Polyclonal antibody to human plasminogen (rhPLG) | 500 ug |
| A022 | Polyclonal antibody to human prostate transglutaminase (TG4) | 500 ug |
| A023 | Monoclonal antibody to N'-ly-L-glutamylpL-lysine-isopeptide bond | 100 ug |
| A024 | Monoclonal Antibody to microbial (bacterial) Transglutaminase | 100 ug |
| A028 | FITC-labeled polyclonal antibody to human TG2 | 200 ug |
| A029 | FITC-labeled polyclonal antibody to human TGI | 200 ug |
| A030 | FITC-labeled polyclonal antibody to human TG3 | 200 ug |
| A031 | FITC-labeled polyclonal antibody to human TG6 | 200 ug |
| A032 | FITC-labeled polyclonal antibody to human factor XIII (A-subunit) | 200 ug |
| A033 | Monoclonal antibody to human TG2 (Catalytic Domain, clone XTG17) | 200 ug |
| A034 | Monoclonal antibody to human TG2 (Beta Sheet Domain, clone XTG 1 1) | 200 ug |
| A035 | Monoclonal antibodies to gliadin (Set No 1) | 1 Set |
| A036 | Monoclonal antibody to human TG2 (Beta Barrel 1 Domain, clone XTG21) | 200 ug |
| A037 | Monoclonal antibody to human TG2 (Beta Barrel 2 Domain, clone XTG1 8) | 200 ug |
| A040 | Polyclonal antibody to human transglutaminase 7 (TG7) | 200 ug |
| A042 | Monoclonal antibody to human TGI (clone XTG3 1) | 200 ug |
| A044 | FITC-labeled polyclonal antibody to human TG5 | 200 ug |
| A046 | D-Dimer monoclonal mouse antibody, clone 3B6 | 100 ug |
| A047 | D-Dimer monoclonal mouse antibody, clone 1 D2 | 100 ug |
| A051 | Biotinylated polyclonal antibody to microbial transglutaminase (MTG) | 50 ug |
| A052 | Biotinylated polyclonal antibody to human factor XIII (A-subunit) | 50 ug |
| A053 | Biotinylated polyclonal antibody to human TG2 | 50 ug |
| A054 | Monoclonal antibody to gliadin (clone XGY6) | 1 mg |
| A057 | Monoclonal antibody to deamidated gliadin | 100 ug |
| A058 | Monoclonal antibody to gliadin (clone XGY5) | 1 mg |
| A059 | Monoclonal antibody to gliadin (clone XGY9) | 1 mg |
| A060 | Monoclonal antibody to gliadin (clone XGY10) | 1 mg |
| A061 | Monoclonal antibody to gliadin (clone XGY 1 6) | 1 mg |
| A062 | Monoclonal antibody to deamidated and non-deamidated gliadin | 100 ug |
| A063 | Monoclonal antibody to gliadin (clone XGY2) | 1 mg |
| A064 | Monoclonal antibody to gliadin (clone XGY4) | 1 mg |
| A065 | Monoclonal antibody to gliadin (clone XGY8) | 1 mg |
| A066 | Monoclonal antibody to gliadin (clone XGY 1 2) | 1 mg |
| A067 | Monoclonal antibody to gliadin (clone XGY 1 5) | 1 mg |
| A068 | Monoclonal antibody to gliadin (clone XGY 1 7) | 1 mg |
| A069 | Monoclonal antibody to gliadin (clone XGY23) | 1 mg |
| A070 | Monoclonal antibody to gliadin (clone XGY24) | 1 mg |
| A071 | Monoclonal antibody to hordein (clone XH4) | 1 mg |
| A072 | polyclonal antibody to mouse tissue Transglutaminse | 200 ug |
| A074 | Polyclonal antibody to human blood coagulation factor XIII (B-subunit) | 200 ug |
| A075 | FITC-labeled polyclonal antibody to mouse TG2 | 200 ug |
| A076 | DD-XLink-mab | 100 ug |
| A077 | FITC-labeled polyclonal antibody to human factor XIII (B-subunit) | 200 ug |
| A078 | Polyclonal antibody to human epidermal transglutaminase (TG3) Protein A | 250 ug |
| A079 | Biotin-DD-XLink-mab | 50 ug |
| A082 | Monoclonal antibody to human TG3 (clone XTG45) | 200 ug |
| A101 | FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg |
| A102 | TG2-Assay Substance. Abz-APE(CAD-DNP)QEA-OH | 10 mg |
| A105 | NQEQVSPLTLLK, alpha2-Antiplasmin peptide (1-12) | 25 mg |
| A106 | (ATTO-48 8TM)cadaveri ne | 1 mg |
| A108 | Ac-(D)-Asp-MA-N le-Nle-Leu-Pro-Trp-Pro-OH | 5 mg |
| A109 | β-Amyloid peptide 1-42 (Aβ 1-42) | 1 mg |
| A112 | (ATTO-532)cadaverine | 1 mg |
| A113 | (ATTO-550)cadaverine | 1 mg |
| A114 | (AnO-647N)cadaverine | 1 mg |
| A115 | (ATTO-700)cadaverme | 1 mg |
| A125 | Factor XIII activation peptide | 10 mg |
| A132 | Ac-WALQRPHYSYPD | 10 mg |
| A139 | Monoclonal antibody to human TG6 (Catalytic Domain, clone XTG52) | 200 ug |
| A140 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG39) | 200 ug |
| A141 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG68) | 200 ug |
| A142 | Monoclonal antibody to human TG6 (Beta Barrel 2 Domain, clone XTG57) | 200 ug |
| A143 | Monoclonal antibody to microbial Transglutaminase (clone XM67) | 200 ug |
| A144 | Monoclonal antibody to microbial Transglutaminase (clone XM68) | 200 ug |
| A145 | Polyclonal Antibody to microbial Transglutaminase | 200 ug |
| A152 | 3-Azido-l -propanamine | 100 mg |
| A153 | 4-Azidobutan-l-amine | 100 mg |
| A154 | Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09) | 200 ug |
| A155 | Monoclonal antibody to human factor XIII (Catalytic Domain, clone XTG02) | 200 ug |
| B001 | Biotinyl-Thr-Val-GIn-GIn-Glu-Leu-OH | 5 mg 25 mg |
| B002 | N-(Biotinyl)cadaverine | 25 mg 100 mg |
| B003 | Boc-DON-Gln-lle-Val-OMez "Boc-DON” | 10 mg |
| B006 | Thr-Val-Gln-Gln-Glu-Leu-OH | 25 mg |
| B007 | Keratinocyte transglutaminase (TGI )-substrate-peptide K5 | 10 mg |
| B008 | Tissue transglutaminase (TG2)-substrate-peptide T26 | 10 mg |
| B009 | Epidermal transglutaminase (TG3)-substrate-peptide E51 | 10 mg |
| B010 | Blood coagulation FXIII-substrate-peptide Fl 1 KA | 10 mg |
| B013 | Neuronal transglutaminase (TG6)-substrate peptide Y25 | 10 mg |
| B014 | Transglutaminase 7 (TG7)-substrate peptide Z3S | 10 mg |
| B015 | Biotin-Ahx-MA-QPL-OMe | 10 mg |
| B017 | Microbial Transglutaminase (MTG)-substrate peptide M48 | 10 mg |
| B019 | Biotin-Ahx-QVPL-OMe | 10 mg |
| C001 | Z-GIn-Gly-OH | 1g |
| C002 | Z-GIn-Gly-CAD-DNS | 25 mg 100 mg |
| C074 | Z-Gln-Gly-CAD-(AnO-488) | 1 mg |
| C075 | Z-Gln-Gly-CAD-(ATTO-532) | 1 mg |
| C076 | Z-Gln-Gly-CAD-(AnO-550) | 1 mg |
| C077 | Z-Gln-Gly-CAD-(ATTO-647N) | 1 mg |
| C078 | Z-Gln-Gly-CAD-(AnO-700) | 1 mg |
| C079 | Z-GIn-Gly-PEG(3)-N3 | 25 mg |
| C080 | Z-Gln-Gly-PEG(11)-N3 | 25 mg |
| C090 | Z-GIn-Gly-CAD-TAMRA | 25 mg |
| C091 | Z-GIn-Gly-CAD-Biotin | 25 mg |
| C092 | Z-Gln-Gly-(PEG1,088), monodisperse | 25 mg |
| C093 | Z-Gln-Gly-(PEG5,000), polydisperse | 25 mg |
| C094 | Tosyl-ε-aminopentyl-CMK | 1 mg |
| C095 | Dansyl-ε-aminopentyl-CMK | 1 mg |
| C102 | MTG Blocker | 10 mg 25 mg |
| D001 | Dansyl-ε-aminohexanoyl-GIn-GIn-lle-Val-OH | 25 mg 100 mg |
| D002 | N-(2,4-Dinitrophenyl)cadaverine | 100 mg |
| D003 | 1,3-Dimethyl-2[(2-oxo-propyl)thio]imidazolium chloride | 100 mg |
| D004 | 1,3-Dimelhyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium | 10 mg |
| D005 | Metalloprotease-Assay-Substance, DABCYL-Ser-Phe-EDANS | 2 mg |
| D006 | N-(Dansyl)cadaverine | 100 mg |
| D007 | Cadaverine | 100 mg |
| D008 | "DALP", DNP-aminohexanoic acid-Lys-aminopropanol | 5 mg |
| D009 | DALP-methyl carbamate | 5 mg |
| D0I 6 | LDN 27219 | 10 mg |
| E018 | ZediXclusive Tissue Transglutaminase EIA | 1 Kit |
| E021 | ZediXclusive Microbial Transglutaminase (MTG) ELISA | 1 Kit |
| E103 | ZediXclusive TG6-ab ELISA (IgA) | 1 Kit (96 wells) |
| E104 | ZediXclusive TG6-ab ELISA (IgG) | 1 Kit (96 wells) |
| F001 | FXIII-Assay Kit | 1 Kit |
| F002 | Tissue Transglutaminase Assay Kit | 1 Kit |
| F004 | Fibrinogen, purified from human plasma | 50 mg |
| F006 | FITC-labeled Fibrinogen | 5 mg |
| F007 | Fibrin Glue (porcine) | 1 Kit |
| F008 | Fibrin Glue (bovine) | 1 Kit |
| F011 | Cross-linked fibrin degradation products, xFDPs | 200 ug |
| F012 | Fibrin degradation products, FDPs | 200 ug |
| G001 | Alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G002 | Deamidated alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G003 | Ac-PLQPEQPFPK(ε-Biotin), Deamidated gliodin peptide | 10 mg |
| G004 | Ac-PEQLPQFEEK(ε-Biotin), Deamidated gliadin peptide | 10 mg |
| G005 | DGPx4 (Fusion protein of 4 deamidated gliadin peptides) | 500 ug |
| G006 | DGPx2 (Fusion protein of 2 deamidated gliadin peptides) | 500 ug |
| G007 | DGPxl (deamidated gliadin peptide) | 500 ug |
| G008 | Omega-5 gliadin | 500 ug |
| G009 | Alpha2-gliadin, 33mer (aa 56-88) | 5 mg |
| G011 | Deamidated alpha2-gliadin, 33mer, (Acetyl-aa56-88-amide, Q65E) | 5 mg |
| G013 | QPFPQPQLPYPQPQ-amide | 10 mg |
| G014 | QPFPQPELPYPQPQ-amide | 10 mg |
| G017 | Biotinylated DGPx1 | 100 ug |
| G018 | Barley albumin and globulin | 5 mg |
| G019 | Barley prolamin (Hordein) | 5 mg |
| G020 | Barley glutelin (Hordenin) | 5 mg |
| G021 | Rye albumin and globulin | 5 mg |
| G022 | Rye prolamin (Secalin) | 5 mg |
| G023 | Rye glutelin (Secalinin) | 5 mg |
| G024 | Corn albumin and globulin | 5 mg |
| G025 | Corn prolamin (Zein) | 5 mg |
| G026 | Corn glutelin (Zeanin) | 5 mg |
| G027 | Rice albumin and globulin | 5 mg |
| G028 | Rice prolamin (Oryzin) | 5 mg |
| G029 | Rice glutelin (Oryzenin) | 5 mg |
| G030 | Spell albumin and globulin | 5 mg |
| G031 | Spelt prolamin | 5 mg |
| G032 | Spelt glutelin | 5 mg |
| G033 | Oat albumin and globulin | 5 mg |
| G034 | Oat prolamin (Avenin) | 5 mg |
| G035 | Oat glutelin (Avenalin) | 5 mg |
| G036 | Wheat albumin and globulin (Leukosin and Edestin) | 5 mg |
| G037 | Wheat prolamin (Gliadin) | 5 mg |
| G038 | Wheat glutelin (Glutenin) | 5 mg |
| G039 | Durum wheat albumin and globulin | 5 mg |
| G040 | Durum wheat prolamin | 5 mg |
| G041 | Durum wheat glutelin | 5 mg |
| G042 | Soy protein, saline soluble fraction | 5 mg |
| G043 | Soy protein, ethanol soluble fraction | 5 mg |
| G044 | Soy protein, propanol/urea/DTE soluble fraction | 5 mg |
| G045 | Millet (Sorghum) albumin and globulin | 5 mg |
| G046 | Millet (Sorghum) prolamin (Kafirin) | 5 mg |
| G047 | Millet (Sorghum) glutelin | 5 mg |
| G048 | L-Glutamic acid γ-monohydroxamate | 100 mg |
| G051 | 26mer gliadin peptide | 250 ug |
| G052 | 33mer gliadin peptide | 250 ug |
| G054 | 33mer DGP | 250 ug |
| G055 | Carrier protein control | 250 ug |
| G056 | DGP and Gliadin peptides (Set No 1) | 1 Set |
| G057 | Alpha2-gliadin, 33mer (aa56-88), TAMRA labeled | 5 mg |
| G058 | Alpha2-gliadin, 33mer (aa56-88), TAMRA and Biotin labeled | 5 mg |
| G101 | Gly-Pro-Arg-Pro-amide | 25 mg |
| I001 | Involucrme, recombinant human | 500 ug |
| K004 | "KxD", Boc-Lys-en-DNS | 10 mg |
| L001 | Substrate Finder Kit | 1 Kit |
| L101 | Biotin TGase Protein Q-Labeling Kit | 1 Kit |
| L102 | PEG1,088 TGase Protein Q-Labeling Kit | 1 Kit |
| L103 | PEG5,000 TGase Protein Q-Labeling Kit | 1 kit |
| L104 | ATTO-488™ TGase Protein Q-Labeling Kit | 1 Kit |
| L105 | ATTO-532™ TGase Protein Q-Labeling Kit | 1 Kit |
| L106 | ATTO-550™ TGase Protein Q-Labeling Kit | 1 Kit |
| L107 | ATTO-647N™ TGase Protein Q-Labeling Kit | 1 Kit |
| L108 | ATTO-700™ TGase Protein Q-Labeling Kit | 1 Kit |
| L201 | Biotin TGase Protein K-Labeling Kit | 1 Kit |
| L202 | PEG1,088 TGase Protein K-Labeling Kit | 1 Kit |
| L203 | PEG5,000 TGase Protein K-Labeling Kit | 1 Kit |
| L204 | ATTO-488™ TGase Protein K-Labeling Kit | 1 Kit |
| L205 | ATTO-532™ TGase Protein K-Labeling Kit | 1 Kit |
| L206 | ATTO-550™ TGase Protein K-Labeling Kit | 1 Kit |
| L207 | ATTO-647N™ TGase Protein K-Labeling Kit | 1 Kit |
| L208 | ATTO-700™ TGase Protein K-Labeling Kit | 1 Kit |
| M001 | MTG-ANiTA-Kit | 1 Kit |
| M003 | Tissue Transglutaminase Pico-Assay Kit | 1 Kit |
| P003 | Prolylendopeptidase from Myxococcus xanthus, recombinant | 150U |
| P004 | PT-Gluten | 1 mg 10 mg |
| P009 | human Pro-Glu-Plasminogen, recombinant | 100 ug |
| P010 | (PEG1,088)amine, monodisperse | 10 mg |
| P011 | (PEG5,000)amine, polydisperse | 10 mg |
| P012 | human Plasmin, recombinant | 100 ug |
| P0U | Urokinase | 1 mg |
| P015 | Streptokinase (bacterial plasminogen activator) | 1 mg |
| P016 | Tissue Plasminogen Activator | 100 ug |
| P111 | PEPperCHIP Pan-Transglutaminase Microarray | 1 Chip |
| P112 | PEPperCHIP Custom Transglutaminase Microarray | 1 Chip |
| P113 | PEPperCHIP Transglutaminase Microarray Service | 1 Sample |
| P114 | PepSlide Analyzer | 3-Month/1-Year/Perpetual License |
| P115 | PEPperCHIP Incubation Tray 3/1 | 1 Tray |
| P116 | PEPperCHIP Staining Kit | 1 Kit |
| P117 | PEPperCHIP Transglutaminase 2 Microarray | 1 Chip |
| P118 | PEPperCHIP Incubation Tray 3/5 | 1 Tray |
| R001 | N-(Tetrametylrhodaminyl)cadaverine | 10 mg |
| R002 | TAMRA-DON | 5 mg 10 mg |
| T001 | Microbial (bacterial) transglutaminase | 25 U; 1 x 250 U;10x 25 U; lx 500 U; 20x 25 U |
| T002 | Human tissue transglutaminase (TG2) | 250 ug 1mg |
| T004 | N-(p-Tosyl)-Gly-Pro-Lys-pNA | 25 mg |
| T006 | Guinea pig liver transglutaminase | 10U |
| T009 | Human keratinocyte transglutaminase (TG1) | 150 ug |
| T011 | Human transglutaminase 7 | 250 ug |
| T013 | Human epidermal transglutaminase, Dispose activated | 200 ug |
| T016 | Microbial (bacterial) Pro-transglutaminase | 250 ug |
| T018 | Inactive human tissue transglutaminase | 250 ug 1 mg |
| T021 | Human neuronal transglutaminase (TG6) | 250 ug |
| T022 | Human tissue transglutaminase (TG2) | 250 ug 1 mg |
| T024 | Human epidermal transglutaminase (TG3) | 200 ug |
| T027 | Human blood coagulation Factor Xlll-A z recombinant | 200 ug |
| T034 | Human tissue transglutaminase (TG2) | 100 ug |
| T035 | Human keratinocyte transglutaminase (TGI) | 150 ug |
| T036 | Transglutaminase Assay Kit, fluorescent, Casein, Dansylcadaverine | 1 Kit |
| T038 | Rat tissue transglutaminase | 250 ug 1 mg |
| T039 | Guinea pig liver transglutaminase, recombinant | 10U |
| T040 | Mouse tissue transglutaminase | 250 ug 1 mg |
| T042 | Human prostate Transglutaminase (TG4) | 100 ug |
| T050 | Human blood coagulation Factor XIII B subunit | 200 ug |
| T051 | Open tTG™ | 250 ug |
| T055 | Tissue Transglutaminase Microassay Kit, colorimetric | 1 Kit |
| T056 | Human alpha thrombin, highly active | 200 U |
| T057 | Inhibited human epidermal transglutaminase | 250 ug |
| T061 | Mouse blood coagulation Factor Xlll-A2 | 200 ug |
| T062 | Dog blood coagulation Factor Xlll-A2 | 200 ug |
| T063 | Human blood coagulation Factor Xlll-A2 , Val34Leu-mutant | 200 ug |
| T064 | Inhibited human neuronal transglutaminase | 250 ug |
| T065 | Rat blood coagulation Factor Xlll-A2 | 200 ug |
| T066 | Pig blood coagulation Factor Xlll-A2 | 200 ug |
| T067 | Human tissue transglutaminase (TG2), endotoxin free | 250 ug 1 mg |
| T070 | Human Factor Xllla, Thrombin activated | 200 ug |
| T072 | Dog tissue transglutaminase | 250 ug 1 mg |
| T086 | Human Transglutaminase 5 | 100 ug |
| T087 | Tridegin | 200 ug |
| T092 | Human blood coagulation Factor Xlll-A2 | 100 ug |
| T101 | 1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride | 10 mg |
| T102 | Mouse Open TG2 | 250 ug 1 mg |
| T106 | Biotinylated human tissue transglutaminase (TG2) | 100 ug 250 ug |
| T108 | Cynomolgus tissue transglutaminase | 250 ug |
| T109 | Cynomolgus open TG2 | 100 ug |
| T1 10 | Recombinant TG2 [E.coli] | 500 ug |
| T1 14 | Blood Coagulation Factor Xlll-Microassay Kit, colorimetric | 1 Kit |
| T117 | Biotinylated inactive hTG2 (Cys277Ser) | 250 ug 1 mg |
| T122 | Recombinant TG2 (insect cells) | 500 ug |
| T123 | Biotinylated human tissue transglutaminase (TG2) | 50 ug |
| T124 | Recombinant TG3 (insect cells) | 400 ug |
| T127 | Biotinylated human blood coagulation Factor XIII | 50 ug |
| T134 | Open tTG™ | 100 ug |
| T139 | Rabbit tissue transglutaminase | 250 ug 1mg |
| T140 | Biotinylated human epidermal transglutaminase | 100 ug |
| T141 | Biotinylated human neuronal transglutaminase | 100 ug |
| T142 | Biotinylated mouse blood coagulation Factor Xlll-A2 | 50 ug |
| T146 | Mouse neuronal transglutaminase | 250 ug |
| T148 | Biotinylated human Open tTG™ | 50 ug 1 mg |
| T149 | Oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T150 | Biotinylated mouse open TG2 | 50 ug |
| T151 | Biotinylated oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T152 | Rabbit blood coagulation Factor Xlll-A2 | 200 ug |
| T153 | Microbial (bacterial) transglutaminase, edotoxin free | 25 U;10x 25 U;20x 25 U |
| T156 | Biotinylated mouse tissue transglutaminase | 250 ug; 1 mg |
| T159 | Pig tissue transglutaminase | 250 ug; 1 mg |
| T160 | Biotinylated cynomolgus tissue transglutaminase | 50 ug |
| T161 | Cynomolgus blood coagulation Factor Xlll-A2 | 200 ug |
| T167 | Short human tissue transglutaminase, aa 1-475 | 250 ug |
| T168 | Human tissue transglutaminase, C23OA mutant | 250 ug;1 mg |
| T169 | Human tissue transglutaminase, R580A mutant | 250 ug;1 mg |
| T173 | Human tissue transglutaminase, R116C mutant | 1 mg |
| T178 | Microbial transglutaminase with C-terminal His6-tag | 25 U;10 x 25 U;20 x 25 U |
| T184 | Cat tissue transglutaminase | 200 ug |
| T187 | Factor XIII activation peptide, recombinant | 500 ug |
| T197 | Coagulation factor XIII, recombinant human Factor Xlll-A2 | 100E;250E |
| T222 | Human alpha Thrombin, recombinant | 100 NIH Units |
| Z004 | Z-Gln-GIn-Pro-Leu-OH | 25 mg |
| Z006 | Z-DON-Val-Pro-Leu-OMe,"Z-DON" | 10 mg |
| Z009 | ZediXclusive Microbial Transglutaminase Assay Kit | 1 Kit |
| Z010 | ZediXclusive Tissue Transglutaminase Assay Kit | 1 Kit |
| Z011 | Z-(D)-DON-Val-Pro-Leu-OMe | 10 mg |
| Z013 | Z-MA-QPL-OMe | 10 mg |
| Z015 | Keillor inhibitor AA9 | 10 mg |
| Z016 | Keillor inhibitor NC9 | 10 mg |
| Z017 | Keillor inhibitor VA4 | 10 mg |

Synaptic Systems为神经科学家和细胞生物学科学家提供研究工具,致力于为神经科学和细胞生物学访方面提供最好的抗体。
Synaptic Systems strives to provide you with the best antibodies in neuroscience and cell biology. Most antibodies are exclusively available from Synaptic Systems and have been developed in-house in close collaboration with renowned experts in the field. Our antibodies are well characterized and known for their excellent quality. We are constantly adding new products and offer attractive licensing conditions.
Synaptic system的主要产品包括:
突触活性区相关抗体
Alzheimer's相关抗体
钙离子结合蛋白相关抗体
细胞粘附分子相关抗体
细胞骨架相关抗体
离子通道相关抗体
神经递质转运体相关抗体
突触后蛋白相关抗体
受体蛋白相关抗体
RNA修饰蛋白相关抗体
SNARE蛋白相关抗体
snRNPs相关抗体
突触粘附蛋白相关抗体
转录因子相关抗体
囊泡相关抗体
其它神经/细胞生物学研究抗体
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Synaptic Systems"> Synaptic Systems
艾美捷科技特约代理Exbio公司产品。Exbio公司是捷克著名的抗体生产商,该公司于学术机构展开广泛的合作,在杂交瘤、重组蛋白和抗体方面始终保持研发力度,持续不断地推出新的产品。
抗体产品主要包括以下领域:Human Immunology、Rodent Immunology、Veterinary Reagents、
Cell Biology、Isotype Control Reagents等,此外还有重组蛋白、试剂盒,以及OEM服务。
EXBIO manufactures and supplies antibodies for world-wide distribution. Sales on an OEM basis and in bulk quantity is the core business activity of the company. Strong Research & Development (hybridoma technology, construction of recombinant proteins and antibodies) in co-operation with academic institutions ensures the continuous addition of important new products.
EXBIO entered the antibody market as a spin-off company of Czech Academy of Sciences in 1990. Continuous economic growth resulted in the movement to our own brand new manufacture facility on February 2003.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Exbio"> Exbio地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18327026838
邮箱:sales@amyjet.com
0.3711